1Ghielmini M, Schmitz S, Cogliatti S, et al. Prolonged treatment with 2-monthly rituximab significantly improves eventfree survival and duration of response in patients with follicular lymphoma:A randomized SAKK Trial[ J]. Blood ,2002,100: 161A.
2Witzig T, Vukov A, Habermann T, et al. Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin' s Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group [ J ]. Blood, 2002,100:361.
3Solal-Celigny P,Salles GA, Brousse N et al. Single 4-dose rituximab treatment for low tumor burden lymphoma(FL) :Survival analyses with a follow-up (F/Up)of at least 5 years[J]. Blood,2004,104: 585.
4Hiddemann W,Fomtpointner R, Kneba M,et al. The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymphoma but not in mantle cell lymphoma : Results of two prospective randomized studies of the German Low Grade Lymphoma Study (GLSG) [J]. Blood,2004,104: 161.
5Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma [J]. J Clin Oncol,2004,22: 2662.
6Czuczman M, Fallon A, Mohr A, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma [ J ]. Semin Oncol, 2002,29( Suppl 2 ) : 36 -40.
7Davis T, Grillo-1opez A, White C, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin' s lymphoma:Safety and efficacy of re-treatment[ J]. J Clin Oncol,2000. 18: 3135.
8Colombat P, Salles G, Brousse N, et al. Rituximab as single first-line therapy for patients with follicular lymphomas with a Low tumor burden clinical and molecular evaluation[ J]. Blood,2001,97: 101.
9Hainsworth J, Litchy S, Burris H, et al. Rituximab as first-line and maintenance therapy for Patients with indolent non-Hodgkin' s Lymphoma[ J]. J Clin Oncol,2002,20: 4261 -4267.
10Martinelli G, Laszlo D, Bertolini F, et al. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin' s lymphoma [ J]. Br J Haematol, 2003. 123: 271 - 277.
